Donor immune cells aim to fight virus in vulnerable patients

NCT ID NCT03425526

Recruiting now Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests whether specially grown donor T cells can safely treat adenovirus infections in people with weakened immune systems, such as cancer patients. The cells are designed to target and kill the virus. The study will check for side effects and see if the infection improves.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: donor T cells (adenovirus-specific cytotoxic T lymphocytes)
What this could lead to: If it works, this could offer a treatment option for dangerous adenovirus infections in people with weakened immune systems.
What could go wrong: This is a very early phase 1 trial with only 16 participants, so it may not work or could cause side effects. The cells are from donors, which carries risks like rejection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADENOVIRUS-RELATED DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adenoviridae infectious disease hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm immunodeficiency disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM IMMUNOCOMPROMISED

Contacts and locations

Locations

M D Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.